CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET ANALYSIS

Central Nervous System Biomarkers MarketSize and Trends

Central Nervous System Biomarkers Market – Drivers

Increasing number of pipeline studies for the development of biomarkers in various disease conditions is expected to boost the central nervous system biomarkers market growth. For instance, in March 1, 2017, Hospices Civils de Lyon, initiated the clinical trial to evaluate predictive value of CSF biomarkers of Alzheimer’s disease (AD) in geriatric patients with new-onset epilepsy.

Biomarkers are becoming crucial in drug discovery and development process. Therefore, increasing number of research for drug development is also expected to propel the central nervous system biomarkers market growth. For instance, in January 2016, The Tufts Center for the Study of Drug Development, estimated that the developing cost of a new drug was US$ 2.6 billion and also suggested that the costs of drug development are increasing at a compound annual growth rate of 8.5%.

However, high cost of validation process such as sample collection & storage and unfavorable reimbursement situation for development and discovery of biomarkers can impede the central nervous system biomarkers market growth.